Controlled-release oxycodone admissions in public and private substance abuse treatment: associations with organizational characteristics.

Controlled-release oxycodone admissions in public and private substance abuse treatment: associations with organizational characteristics. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Controlled-release oxycodone admissions in public and private substance abuse treatment: associations with organizational characteristics. Abstract Text:

Hannah K Knudsen,Lori J Ducharme,Paul M Roman,

Although non-medical use of controlled-release (CR) oxycodone is increasing, little is known about the substance abuse treatment facilities serving individuals dependent on this medication. This study examines the associations between the characteristics of treatment organizations and two dependent variables: any CR-oxycodone admissions and the number of CR-oxycodone admissions in the past six months. Face-to-face interviews were conducted with administrators of 363 publicly funded and 401 privately funded treatment centers in the US. Publicly funded non-profit organizations were less likely to have treated this population than government- owned, privately funded non-profit, and for-profit treatment centers. Some evidence indicated the availability of pharmacotherapies and detoxification services were associated with the dependent variables. Twelve-step programs were more likely to have treated oxycodone-dependent clients. Rural facilities treated significantly more clients than those in metropolitan areas. The high prevalence of CR-oxycodone admissions suggests the need for widespread training of treatment providers regarding treatment for CR-oxycodone dependence.

Controlled-release oxycodone admissions in public and private substance abuse treatment: associations with organizational characteristics. Publishing Authors By Initials

HK Knudsen,LJ Ducharme,PM Roman,

For similar population characteristics: population: urban population research abstracts see: population characteristics: population: urban population research

PUBMED ID PMID:

MEDLINE DATE:

Controlled-release oxycodone admissions in public and private substance abuse treatment: associations with organizational characteristics. Journal Published:

PUBLICATION TYPE: Research Support, N.I.H., Extr

Journal: Journal of addictive diseases : the official journ

VOLUME: 26

Page Numbers: 41-50

Journal Abbreviation:

ISSN: 1055-0887

DAY: 3

MONTH: 12

YEAR: 2007

Controlled-release oxycodone admissions in public and private substance abuse treatment: associations with organizational characteristics. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9107051

Controlled-release oxycodone admissions in public and private substance abuse treatment: associations with organizational characteristics. Keywords Mesh Terms:

KEYWORDS: Urban Population

MESH TERMS: statistics & numerical data

Chemical & Substance for Abstract: Controlled-release oxycodone admissions in public and private substance abuse treatment: associations with organizational characteristics. Information

Substance Name: Oxycodone

Registry Number: 76-42-6

Grant and Affiliation Information for Controlled-release oxycodone admissions in public and private substance abuse treatment: associations with organizational characteristics.

AFFILIATION: Center for Research on Behavioral Health and Human Services Delivery, University of Georgia, Athens, GA 30602-2401, USA. hknudsen@uga.edu

Country: United States

AGENCY: United States NIDA

GRANT: R01-DA-14482

ACRONYM: DA

MEDLINETA: J Addict Dis

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Controlled-release oxycodone admissions in public and private substance abuse treatment: associations with organizational characteristics Related Publications

• Acrylic injectable and self-curing formulations for the local release of bisphosphonates in bone tissue.
• Alveolar type II cells from ethanol-fed rats produce a fibronectin-enriched extracellular matrix that promotes monocyte activation.
• Autism: transient in utero hypothyroxinemia related to maternal flavonoid ingestion during pregnancy and to other environmental antithyroid agents.
• Black thyroid syndrome.
• Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.
• Controlled-release oxycodone admissions in public and private substance abuse treatment: associations with organizational characteristics.
• Counselor emotional exhaustion and turnover intention in therapeutic communities.
• Editorial commentary.
• Effects of latanoprost, timolol and GLC756, a novel dopamine D(2) agonist and D(1) antagonist on LTC(4) release after rat mast cell activation.
• Elevations in renal interstitial hydrostatic pressure and 20-hydroxyeicosatetraenoic acid contribute to pressure natriuresis.
• Environmental neurology: a promising new field of practice and research.
• Environmental vascular risk factors: new perspectives for stroke prevention.
• Exploratory activity in Drosophila requires the kurtz nonvisual arrestin.
• Extracellular cysteine/cystine redox potential controls lung fibroblast proliferation and matrix expression through upregulation of transforming growth factor-beta.
• Increased fibronectin expression in lung in the setting of chronic alcohol abuse.
• Mouse smad8 phosphorylation downstream of BMP receptors ALK-2, ALK-3, and ALK-6 induces its association with Smad4 and transcriptional activity.
• Nicotine alters lung branching morphogenesis through the alpha7 nicotinic acetylcholine receptor.
• Phase II clinical trial of docetaxel in refractory squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study.
• Racial and ethnic disparities in SSRI availability in substance abuse treatment.
• Referral pathways and diagnosis: UK government actions fail to recognize complexity of lymphoma.
• Research network involvement and addiction treatment center staff: counselor attitudes toward buprenorphine.
• Research participation and turnover intention: An exploratory analysis of substance abuse counselors.
• Role of endogenous CYP450 metabolites of arachidonic acid in maintaining the glomerular protein permeability barrier.
• Roman tunnelling tool.
• The adoption of medications in substance abuse treatment: associations with organizational characteristics and technology clusters.
• The effects of caffeine on the preterm sheep ductus arteriosus.
• The selfless geneticist.
• The use of antidepressant medications in substance abuse treatment: the public-private distinction, organizational compatibility, and the environment.
• Trends in the adoption of medications for alcohol dependence.
• [Neurocysticercosis: a public health perspective]